| Bioactivity | Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence[1]. |
| Target | ENPP1 |
| Name | Enpp-1-IN-19 |
| CAS | 2738583-25-8 |
| Formula | C16H16N4O3S |
| Molar Mass | 344.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Cho Y et al. Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy. J Med Chem. 2023 Nov 23;66(22):15141-15170. |
Enpp-1-IN-19
CAS: 2738583-25-8 F: C16H16N4O3S W: 344.39
Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). En
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.